Skip to main content
. Author manuscript; available in PMC: 2017 Nov 1.
Published in final edited form as: Ann Rheum Dis. 2016 Jan 19;75(11):1998–2006. doi: 10.1136/annrheumdis-2015-208410

Figure 5.

Figure 5

DNA methylation level of the IFI44L promoter in peripheral blood mononuclear cells (PBMCs) of healthy persons treated with interferon α (IFN-α) or serum from patients with systemic lupus erythematosus (SLE). (A) and (B) show that there is no significant difference in DNA methylation levels of Site1 and Site2 within the IFI44L promoter between healthy PBMCs treated with IFN-α (1000 U/L) and untreated controls. (C) and (D) show that DNA methylation levels of Site1 and Site2 within the IFI44L promoter are not significantly different in healthy PBMCs treated with 10% serum from patients with SLE compared with untreated controls. All data represent the mean ± SD of three independent experiments per group.